The process of spermatogenesis produces more than 1,000 sperm per second in normal males. This productivity comes, in part, from a special cell type called the spermatogonial stem cell. The staying power of this stem cell has allowed many men, including Robert DeNiro and Pablo Picasso, to father children after the age of 65.
Yet spermatogonial stem cells have not been well studied in humans, and attempts to grow them in the lab for clinical purposes have had limited success. In a study published today in Cell Reports, researchers at the University of California San Diego used single-cell RNA sequencing to develop a clearer picture of human spermatogonial stem cells and the formation of sperm. According to the researchers, these findings open the possibility that spermatogonial stem cell transplants could be developed to treat male infertility.
“Single-cell RNA sequencing determines the activity of hundreds of genes in the genomes of single cells," says senior author Miles Wilkinson. “Because each cell type has a different combination of active genes, this technique allows new cell types to be identified. Applying this approach to the testis, we uncovered many different stages of sperm precursor cells in human testes.”
In adult human testes, the researchers identified several cell subtypes that likely include spermatogonial stem cells. They also found cells with the characteristics of spermatogonial stem cells in human newborns.
“Given that spermatogonial stem cells are not necessary for generating sperm until puberty,” Wilkinson adds, “this finding in newborns raises the possibility that these cells perform as-of-yet unknown functions in infants and young children.”
Their study also identified many unique biomarkers that define spermatogonial stem cells. These biomarkers, which they detected with specific antibodies, allowed the researchers to efficiently capture human spermatogonial stem cells. Additionally, Wilkinson’s team identified the genes active in other cells that support spermatogonial stem cells. The findings may help researchers develop protein cocktails that drive spermatogonial stem cell proliferation in the laboratory, allowing them to scale up enough of the cells for clinical applications.
“This was a proof-of-principal for future clinical studies to use spermatogonial stem cell therapy as a means to treat men suffering from infertility, including cancer patients rendered infertile by chemotherapy,” Wilkinson says.
Image: UC San Diego School of Medicine researchers identified several sperm cell subtypes and biomarkers that will help them isolate spermatogonial stem cells. Image courtesy of UC San Diego Health.